Zentalis Pharmaceuticals (NASDAQ:ZNTL) Earns “Neutral” Rating from Wedbush

Zentalis Pharmaceuticals (NASDAQ:ZNTL)‘s stock had its “neutral” rating reaffirmed by research analysts at Wedbush in a report issued on Friday,RTT News reports. They presently have a $4.00 target price on the stock. Wedbush’s price target would indicate a potential upside of 80.18% from the company’s previous close.

Several other brokerages have also recently commented on ZNTL. Guggenheim decreased their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 15th. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Friday, November 15th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $10.00.

Zentalis Pharmaceuticals Price Performance

NASDAQ ZNTL opened at $2.22 on Friday. Zentalis Pharmaceuticals has a 12 month low of $2.13 and a 12 month high of $18.07. The company has a market capitalization of $158.20 million, a P/E ratio of -0.89 and a beta of 1.86. The company’s 50 day simple moving average is $3.05 and its 200 day simple moving average is $3.34.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.36. On average, analysts anticipate that Zentalis Pharmaceuticals will post -2.48 earnings per share for the current year.

Institutional Trading of Zentalis Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. increased its position in Zentalis Pharmaceuticals by 63.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock worth $50,000 after buying an additional 5,333 shares during the last quarter. Carson Advisory Inc. lifted its holdings in Zentalis Pharmaceuticals by 55.8% in the 3rd quarter. Carson Advisory Inc. now owns 24,570 shares of the company’s stock worth $90,000 after purchasing an additional 8,800 shares during the last quarter. Erste Asset Management GmbH bought a new stake in Zentalis Pharmaceuticals during the third quarter worth approximately $37,000. Paloma Partners Management Co acquired a new position in Zentalis Pharmaceuticals during the third quarter valued at approximately $37,000. Finally, 49 Wealth Management LLC raised its position in shares of Zentalis Pharmaceuticals by 81.7% in the third quarter. 49 Wealth Management LLC now owns 22,558 shares of the company’s stock valued at $83,000 after purchasing an additional 10,145 shares during the period.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.